CTOs on the Move


 
Cibus is part of the multi-billion-dollar plant seed industry. Cibus leads the new era of high throughput gene editing technology that can develop plant traits precisely at a fraction of the time and cost of conventional breeding. Cibus is not a seed company. We are a technology company that uses gene editing to develop plant traits. Cibus licenses its traits to seed companies for royalties on seeds that use its traits. Cibus` target market is Productivity Traits” that improve yields, lower input costs such as chemicals and increase the sustainability and profitability of farming. We has a pipeline of six ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.cibus.com
  • 6455 Nancy Ridge Drive
    San Diego, CA USA 92121
  • Phone: 858.450.0008

Executives

Name Title Contact Details

Funding

Cibus raised $70M on 06/26/2018

Similar Companies

Promab Biotechnologies

Promab Biotechnologies is a Albany, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Scout.com Inc

Scout.com Inc is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pebble Labs

Pebble Labs Inc. is a biotechnology company developing solutions to safely and sustainably increase natural crop yield and food security. Our mission is to develop breakthrough disruptive technologies that address the greatest agricultural, aquacultural, and environmental challenges facing the globe.

Abivax

Abivax is developing therapies that modulate the body`s natural immune system machinery. A clinical-stage company, Abivax leverages its immune enhancing and antiviral platforms to develop drug candidates to treat inflammatory diseases, viral diseases and liver cancer. Abivax is based on innovative research driven by the idea of modulating the body`s natural immune system mechanisms to treat diseases.

Pharmagen

Pharmagen purifies and distributes safe drinking water through its chain of open water shops in Pakistan, where water contamination is a major challenge.